Tor McCaul – Managing Director – Comet Ridge Limited (ASX: COI) is a publicly listed Australian energy company focused on the development of natural ga
Copyright 2023 – Finance News Network
Source: Finance News Network
05 Apr 2023 - North Stawell Minerals Limited (ASX:NSM) CEO Russell Krause provides an update, discussing the company's progress to date, the most prospective targets, and milestones ahead.
Read More12 May 2021 - Galan Lithium (ASX:GLN) Managing Director Juan Pablo Vargas de la Vega provides an update on they company's key Hombre Muerto lithium brine project in the Catamarca province of Argentina.
Read More21 Jul 2021 - icetana (ASX:ICE) CEO and Managing Director Matt Macfarlane provides an update for the June quarter 2021.
Read More05 Feb 2021 - Centuria Office REIT (ASX:COF) Fund Manager Grant Nichols discusses 1H21 highlights, the market conditions for leasing, and the outlook and trends for office markets.
Read More05 Jul 2021 - icetana Limited (ASX:ICE) CEO & Managing Director Matt Macfarlane talks about the company's AI software, which dramatically improves active security monitoring by learning normal movement patterns and highlighting abnormal movement in real time.
Read More23 Sep 2024 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses the company's latest results in head and neck cancer.
Read More10 Oct 2023 - Harry Fisher - Project Manager - Benchmark’s prices and data empowers clients: from critical mineral contracts to EV battery supply chain investments and government policy.
Read More05 Aug 2020 - Centuria Office REIT (ASX:COF) Fund Manager, Grant Nichols talks full year 2020 results, portfolio metrics and guidance.
Read More23 Apr 2021 - Capral Limited (ASX:CAA) Managing Director Tony Dragicevich talks about the company's strong FY20 results despite COVID, its product mix, operating environment and outlook.
Read More27 Apr 2020 - Kazia Therapeutics (ASX:KZA) CEO & MD, Dr. James Garner talks about its Phase II interim results for its glioblastoma drug candidate paxasilib, its pivotal GBM AGILE Phase II clinical study to commence 2H20 and value drivers as the company moves toward registration.
Read More
